Advisa MRI Combines Advanced Pacing Technology With Proven MRI Access.

Second-generation MR-conditional pacemaker combines advanced pacing technology with MRI access

 

February 18, 2013
Advisa DR MRI SureScan Pacing System Medtronic Inc. FDA Approval

The Advisa MRI SureScan pacing system is Medtronic’s second-generation MR-conditional pacemaker and is the first system to combine the most advanced pacing technology with proven MRI access. It received U.S. Food and Drug Administration (FDA) approval in February 2013.

Medtronic’s Advisa MRI pacing system provides physicians with innovative technology that will benefit their patients, including the MVP (Managed Ventricular Pacing) algorithm, which is proven to reduce unnecessary ventricular pacing.[1] Additional Advisa features include:

  • Complete automaticity with Ventricular and Atrial Capture Management (VCM and ACM) to eliminate manual threshold checks and extend longevity of the device by up to one year.[2]
  • Diagnostics, such as the Cardiac Compass Report, and AF management tools that assist physicians in the early detection and treatment of atrial fibrillation.
  • Remote monitoring via Medtronic’s CareLink Network, which transmits comprehensive arrhythmia and diagnostic device data to a physician’s clinic.
  • Rate Drop Response that identifies abrupt cardiac slowing and responds by pacing the heart at an elevated rate, which may reduce the frequency of syncope (fainting) in patients with apparent cardio-inhibitory vasovagal syncope.[3], [4]
  • High upper tracking rate to provide pacing support at higher heart rates for active and younger patients.

This system is the latest addition to a growing number of Medtronic devices, which are designed for MRI access, including the SynchroMed II programmable drug infusion system available worldwide and the SureScan neurostimulation systems for the management of chronic pain that are available in Europe. In addition, SureScan pacing systems — including Advisa MRI — are available worldwide.

For more information: www.medtronic.com

 

References:

1. Gillis AM, Pürerfellner H, Israel CW, et al. Reduction of unnecessary ventricular pacing due to the Managed Ventricular Pacing (MVP) mode in pacemaker patients: Benefit for both sinus node disease (SND) and AV block (AVB) indications. Heart Rhythm. May 2005;2(5):S40. Abstract AB21-1.

2. Rosenthal LS, Mester S, Rakovec P, et al. Factors influencing pacemaker generator longevity: results from the complete automatic pacing threshold utilization recorded in the CAPTURE Trial. Pacing Clin Electrophysiol. August 2010;33(8):1020-1030.

3. Nordlander R, Hedman A, Phersson SK. Rate responsive pacing and exercise capacity—a comment. PACE. 1989;12:749-751.

4. Stone J, Crossley G. Current sensor technology for heart rate modulation by artificial pacing. Clinical Electrophysiology Review. 1999;3:10-14.